Huntington’s disease disrupts genetic "traffic lights," keeping genes green when they should be red. These genetic traffic jams may act to speed brain cell aging and faulty traffic cops fail to stop the chaos. What does this mean for HD?
Hidden twists in the Huntington’s disease gene could shift symptoms by over a decade! Scientists have uncovered rare “genetic dams” that shape when HD begins - sometimes dramatically
Votoplam, the daily pill from PTC Therapeutics, has met its primary endpoint in the PIVOT-HD clinical trial - it can lower huntingtin protein levels. This latest data update also provides insights into safety, biomarkers, and clinical measures.
Heart health has been linked to lower levels of NfL, a key biomarker of brain cell damage in Huntington’s disease. This suggests heart-healthy habits - like exercise and diet - may have an effect on protecting the brain & keeping NfL in check.
Huntington’s disease slows the cell’s protein factory, causing production line jams & toxicity. A faulty blueprint & missing factory assistant worsen errors. Targeting production slowdowns, not just misfolded products, may help fix the assembly line.
HDBuzz has ramped up to match the accelerating pace of Huntington’s disease research. April 2025 brought us insight on somatic expansion, replacing lost brain cells, and clinical trial updates. Read on for the highlight reel from this month!
A new study shows that lowering MSH3, a key DNA repair protein, with antisense oligonucleotide (ASO) therapy can stop CAG repeat expansions in HD patient-derived brain cells. This could be a promising way to slow symptom onset and progression.
Avoid the hype: HDBuzz has Ten Golden Rules for navigating news stories or press releases about Huntington's disease.
Roche gave an update this week about GENERATION HD2, testing the HTT-lowering drug tominersen in people with HD. The trial is continuing, but only the higher dose will move forward. What does this update mean for the HD community and this trial?